Back
Speaker illustration

Professor Klaus G Parhofer

Ludwig Maximilians University, Munich (Germany)

Klaus Parhofer is a Professor of Endocrinology and Metabolism at the University in Munich, Germany, with a special focus on metabolic diseases.

Presentations Articles

Underestimation of cardiovascular risk in four European countries: results from the prospective, non-interventional MILOS study

Event: ESC Congress 2025

Topic: Cardiovascular Risk Assessment

Session: Global health trends (2)

Access
Like
Thumbnail

Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial

Event: ESC Congress 2025

Topic: Lipid-Lowering Agents

Session: Cardiotoxicity and protection: from bench to bedside

Access
Like
Thumbnail

Panel discussion and Q&A

Event: ESC Congress 2024

Topic: Lipid-Lowering Agents

Session: Cholesterol lowering in high cardiovascular risk patients with comorbidities: closing gaps and future opportunities

Access
Like
Thumbnail

Unmet needs: real-world evidence reveals treatment gaps in patients with diabetes and obesity

Event: ESC Congress 2024

Topic: Lipid-Lowering Agents

Session: Cholesterol lowering in high cardiovascular risk patients with comorbidities: closing gaps and future opportunities

Access
Like
Thumbnail

Clinical experience with add-on oral therapy: patient cases..

Event: ESC Congress 2022

Topic: Drug therapy

Session: Optimising the lipid management of high and very high cardiovascular risk patients

Access
Like
Thumbnail

Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017-2020

Event: ESC Congress 2022

Topic: m-Health & Mobile Apps

Session: Digital health innovation: from artificial intelligence to clinical decision support

Access
Like
Thumbnail

When and how to treat hypertriglyceridemia.

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacology and Pharmacotherapy

Session: Lipid lowering beyond LDL-cholesterol and statins

Access
Like
Thumbnail

PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: final study and cardiovascular subgroup data

Event: ESC Congress 2018

Topic: Drug therapy

Session: Preventive cardiology / Lipids

Access
Like
Thumbnail

The ODYSSEY ESCAPE study: rationale, design, patient characteristics at baseline, and final study data

Event: ESC Congress 2016

Topic: Lipids

Session: Lipids and coronary artery disease

Access
Like
Thumbnail

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources